Earnings summaries and quarterly performance for NextPlat.
Executive leadership at NextPlat.
Board of directors at NextPlat.
Research analysts covering NextPlat.
Recent press releases and 8-K filings for NXPL.
NextPlat's GTC Subsidiary Expands IoT Offerings with Telit Cinterion Agreement
NXPL
Product Launch
New Projects/Investments
- NextPlat Corp's Global Telesat Communications Ltd (GTC) subsidiary has expanded its Internet of Things (IoT) product portfolio through a new agreement with Telit Cinterion, a global leader in intelligent IoT solutions.
- This partnership enhances GTC's offerings with advanced AI-powered 5G and edge computing solutions, allowing it to expand sales within fast-growing industrial and enterprise IoT sectors such as manufacturing, agriculture, transport, logistics, energy, and utilities.
- The global IoT market is currently valued at approximately $1.18 trillion and is projected to grow to about $2.65 trillion by 2030, representing a compound annual growth rate of about 11.4%.
- The agreement enables GTC to further participate in the rapid growth and adoption of IoT alongside Telit Cinterion, which provides secure, scalable, and AI-driven products and services.
Dec 16, 2025, 1:01 PM
NextPlat Expects Significant Sequential Q4 2025 340B Revenue Growth
NXPL
Revenue Acceleration/Inflection
New Projects/Investments
M&A
- NextPlat anticipates nearly 75% sequential quarterly revenue growth in 340B contract revenue for the fourth quarter of 2025, attributed to new business initiatives implemented in the second half of 2025.
- Based on preliminary review from October through early December 2025, these efforts are expected to produce over 12,000 additional 340B and contracted prescriptions, driving sequential growth in quarterly volumes compared to the third quarter of 2025.
- The company is actively exploring potentially accretive joint venture and acquisition/merger opportunities to expand its pharmacy services business.
- Rodney Barreto, NextPlat's Chairman, has taken an expanded role in business development activities, which has already resulted in two revenue-generating healthcare contracts secured earlier this year.
Dec 10, 2025, 1:01 PM
NextPlat Corp Reports Third Quarter 2025 Results
NXPL
Earnings
Share Buyback
Demand Weakening
- NextPlat Corp reported consolidated revenue of approximately $13.8 million for the third quarter of 2025, a decrease from $15.4 million in the prior year quarter, while the net loss attributable to common shareholders decreased by approximately 48% to $2.2 million, or ($0.08) per diluted share.
- Operating expenses for Q3 2025 decreased to approximately $4.7 million (excluding non-recurring expenses) from $7.8 million in Q3 2024, reflecting cost-cutting measures including reduced stock-based compensation, executive compensation, and headcount.
- The company ended the quarter with approximately $13.9 million in cash and repurchased 130,549 common shares under its authorized share repurchase program.
- Management anticipates accelerated sequential improvements in Q4 2025 and into 2026, driven by ongoing cost reductions and increased prescription volumes in its healthcare segment.
Nov 13, 2025, 2:51 PM
NextPlat Reports Q3 2025 Financial Results and Operational Improvements
NXPL
Earnings
Share Buyback
Management Change
- NextPlat (NXPL) reported total revenue of $13.8 million for Q3 2025, an 11% decrease compared to the prior year quarter, with a gross profit margin of 19.9%.
- The company significantly reduced total operating expenses by nearly 40% to $4.7 million in Q3 2025 compared to the prior year.
- Operational improvements included a 50-person reduction in employee headcount since the start of the year, resulting in approximately $200,000 in monthly payroll savings, and a rebound in the 340B business with over a 140% rise in monthly contract revenue in October compared to its lowest month.
- NXPL repurchased 130,549 common shares during Q3 2025 under its authorized program and ended the quarter with $13.9 million in cash.
- Management views Q3 2025 results as the low point and aims to achieve operational break-even in the second half of 2026.
Nov 13, 2025, 1:30 PM
NextPlat Reports Q3 2025 Financial Results
NXPL
Earnings
Share Buyback
Revenue Acceleration/Inflection
- NextPlat Corp reported consolidated revenue of approximately $13.8 million for the quarter ended September 30, 2025, which is a decrease from approximately $15.4 million in the prior year quarter, primarily due to a decline in Healthcare Operations.
- The net loss attributable to NextPlat Corp common shareholders for Q3 2025 decreased by approximately 48% to approximately $2.2 million, or ($0.08) per diluted share, compared to a net loss of approximately $4.2 million, or ($0.22) per diluted share, in Q3 2024.
- Operating expenses for Q3 2025 decreased to approximately $4.7 million (excluding $3.7 million in non-recurring expenses) from approximately $7.8 million in the prior year quarter, reflecting the impact of cost-cutting initiatives.
- The company ended the quarter with approximately $13.9 million in cash and repurchased 130,549 common shares during Q3 2025 under its authorized share repurchase program.
- NextPlat anticipates accelerated sequential improvements in Q4 2025 and into 2026, driven by increased prescription volumes in its healthcare segment and further reductions in operating expenses.
Nov 13, 2025, 1:03 PM
NextPlat's Healthcare Division Awarded Multi-State Prescription Fulfillment Contract
NXPL
New Projects/Investments
- NextPlat Corp's PharmcoRx subsidiary has been awarded a new multi-state prescription fulfillment services contract from DevotedDOc.
- Under the exclusive agreement, PharmcoRx will begin prescription fulfillment services for patients in Florida and Georgia in November.
- The company is working to expand its fulfillment services nationally beyond Florida and Georgia, as PharmcoRx is also a licensed non-resident pharmacy in states such as Arizona, Colorado, and New York.
- DevotedDOc is a virtual medical group providing services including urgent care, Medication-Assisted Treatment (MAT) for opioid use disorder, and compounded alternatives to GLP-1s for weight loss and Hormone Replacement therapy (HRT).
Nov 5, 2025, 1:03 PM
NextPlat Receives Nasdaq Minimum Bid Price Extension
NXPL
Delisting/Listing Issues
- NextPlat Corp has been granted an additional 180-calendar-day extension by Nasdaq to regain compliance with the minimum bid price requirement.
- The company now has until April 27, 2026, to ensure its shares maintain a closing bid price of at least US$1.00 per share for a minimum of ten consecutive business days.
- NextPlat plans to take necessary actions, including a potential reverse stock split, to cure the deficiency.
- Failure to meet the requirement by the deadline could result in a delisting notification, subject to an appeal process.
Oct 29, 2025, 12:01 PM
NextPlat Updates Shareholders on Operational Improvements, Business Growth, and Share Buyback
NXPL
Product Launch
Share Buyback
Management Change
- NextPlat has made significant operational progress, including re-aligning its healthcare management team and implementing measures expected to contribute up to an additional $1.0 million in yearly overhead reductions starting at the end of the current quarter, building on previous savings.
- The company secured new healthcare contracts in Q3, expanded a government contractor subcontract, and re-engaged a major client, while also commencing a technology upgrade for its ClearMetrX platform.
- In its Communications segment, NextPlat is seeing increased transaction volumes and record high-margin recurring airtime revenue, with a 170% year-on-year increase in services from its EVERYWHERE Communications distribution agreement.
- NextPlat launched its Florida Sunshine brand of vitamins and supplements in September, with sales expected to begin in the Chinese market via Alibaba Tmall Global in late Q4 2025. The company also repurchased shares in September and plans to continue the buyback program after the Q4 blackout period.
Oct 8, 2025, 12:02 PM
NextPlat Launches Florida Sunshine Brand and Gains China Market Approval
NXPL
Product Launch
New Projects/Investments
- NextPlat Corp. has officially launched its Florida Sunshine brand of premium vitamins and supplements in domestic and international markets, including the United States, the UK, and multiple European markets.
- The company is also preparing for entry into the large Chinese market on Alibaba's Tmall Global following approval, with sales expected to begin in the fourth quarter of 2025.
- The product rollout will be supported by an AI-powered digital advertising platform and a Shopify Preferred Partner advertising team.
- NextPlat notes that changes to import tariffs on U.S.-produced goods in China could negatively impact sales of its Made-In-USA Florida Sunshine products.
Sep 16, 2025, 12:02 PM
NextPlat Expands Healthcare Operations with New Leadership and Investments
NXPL
Management Change
New Projects/Investments
Hiring
- NextPlat Corp announced a strategic expansion of its healthcare operations, including new senior leadership appointments and investments.
- Birute Norkute was named Vice President of Healthcare Operations, overseeing NextPlat's healthcare and pharmacy businesses.
- Alexis Fernandez was appointed Director of Pharmacy, bringing over 20 years of clinical and administrative pharmacy experience.
- The company is making investments into PharmcoRx to support increased growth and profitability, including dedicated sales and marketing professionals focused on securing 340B and Long-Term Care (LTC) contracts, and has begun a technology upgrade cycle.
Aug 26, 2025, 12:02 PM
Quarterly earnings call transcripts for NextPlat.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more